Comprehensive Cancer Treatment

China's comprehensive cancer treatment programs offer international patients access to world-class oncological care combining advanced technology, innovative therapies, and significantly lower costs than Western alternatives. China's oncologists treat more cancer patients than anywhere else in the world — the country sees approximately 4.5 million new cancer cases annually — creating a depth of clinical experience and therapeutic expertise that is unmatched globally. China's cancer treatment capabilities encompass the full spectrum of modern oncology: surgical oncology including minimally invasive and robotic-assisted tumor resection, radiation oncology with the latest technologies (IMRT, VMAT, SBRT, proton therapy, and heavy ion therapy), medical oncology with advanced chemotherapy regimens, targeted therapy, and immunotherapy, interventional oncology including TACE (transarterial chemoembolization) and ablation techniques, and integrative oncology combining conventional treatment with evidence-based traditional Chinese medicine. China has emerged as a global leader in several cancer treatment areas. Immunotherapy — particularly PD-1/PD-L1 inhibitors — has been revolutionized by Chinese-developed drugs including tislelizumab (Baiji'an/百济神州), sintilimab (达伯舒), and camrelizumab (艾瑞卡), which have demonstrated excellent efficacy in clinical trials and are available at a fraction of the cost of imported immunotherapy drugs. CAR-T cell therapy, pioneered in part by Chinese researchers, is available at select centers for hematological malignancies at costs significantly below Western prices. Proton and heavy ion therapy centers in Shanghai (Shanghai Proton and Heavy Ion Center — SAPHI) offer the most advanced radiation treatment technology for select solid tumors. China's interventional oncology capabilities are world-leading. The country pioneered many interventional techniques for liver cancer treatment, and Chinese interventional radiologists perform the highest volumes of TACE procedures globally. For hepatocellular carcinoma — China's most common cancer — treatment outcomes at leading Chinese centers are among the world's best. Similarly, China's expertise in nasopharyngeal carcinoma treatment is globally recognized, with cure rates for early-stage disease exceeding 90%. Beijing's Peking University Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital, and PLA General Hospital (301 Hospital) are China's premier comprehensive cancer centers. Shanghai's Fudan University Shanghai Cancer Center and Shanghai Chest Hospital provide outstanding multidisciplinary cancer care. Chengdu's Sichuan Cancer Hospital serves as the oncology hub for western China with advanced treatment capabilities across all tumor types. Treatment costs vary widely by modality: surgery $3,000-15,000, standard chemotherapy cycles $200-1,000, immunotherapy $500-2,000 per cycle (compared to $5,000-15,000 for imported drugs), radiation therapy courses $5,000-20,000 (proton therapy $20,000-35,000 vs. $100,000+ in the US), and targeted therapy $500-3,000 per month. China's role in global cancer drug development has expanded dramatically over the past decade, with Chinese pharmaceutical companies now contributing significantly to the worldwide pipeline of novel oncology therapeutics. The development of domestically produced PD-1 and PD-L1 inhibitors — including tislelizumab, sintilimab, camrelizumab, and toripalimab — has democratized access to immunotherapy both within China and increasingly in international markets. These drugs have demonstrated non-inferior or superior efficacy compared to imported checkpoint inhibitors in multiple cancer types, and their significantly lower cost makes them accessible to patients who might otherwise be unable to afford immunotherapy treatment. For international patients, this means access to cutting-edge immunotherapy at a fraction of the cost charged for imported drugs, with clinical outcomes supported by robust phase III trial data published in leading international medical journals. The integration of traditional Chinese medicine into cancer treatment protocols represents another distinctive feature of Chinese oncological practice. While TCM is never used as a substitute for conventional cancer treatment, it is routinely incorporated as a complementary modality to manage treatment-related side effects and support overall patient wellbeing. Chinese herbal formulas designed to reduce chemotherapy-induced nausea, protect bone marrow function during treatment, improve appetite and nutritional status, and alleviate cancer-related fatigue are prescribed based on individualized TCM pattern diagnosis. Acupuncture has demonstrated efficacy in clinical trials for managing chemotherapy-induced nausea and vomiting, cancer-related pain, and peripheral neuropathy caused by neurotoxic chemotherapy agents. This integrative approach to cancer care, combining the most advanced conventional treatments with evidence-based complementary therapies, offers international patients a comprehensive treatment experience that addresses not only the cancer itself but also the impact of treatment on quality of life. For international patients seeking cancer treatment in China, the coordination process begins with a comprehensive review of medical records, pathology reports, and imaging studies, often facilitated through secure digital platforms before travel. The hospital's international patient office assigns a dedicated coordinator who manages all aspects of the treatment journey, including scheduling multidisciplinary tumor board review, arranging necessary additional testing, coordinating between different specialty departments, and managing logistics such as accommodation near the treatment center and transportation. The multidisciplinary tumor board, a standard feature at China's top cancer centers, brings together surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and TCM practitioners to develop a comprehensive, individualized treatment plan that integrates all available therapeutic modalities. This collaborative approach ensures that patients benefit from the collective expertise of multiple specialists rather than the perspective of a single practitioner, maximizing the likelihood of optimal treatment selection and sequencing for their specific cancer type, stage, and individual health status.